{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:04Z","timestamp":1792013104422,"version":"4.4.0"},"reference-count":44,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AHMT"],"DOI":"10.2147\/ahmt.s303456","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T03:06:05Z","timestamp":1621393565000},"page":"55-66","source":"Crossref","is-referenced-by-count":21,"title":["Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review"],"prefix":"10.2147","volume":"Volume 12","author":[{"given":"Catherine","family":"Copley-Merriman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Juniper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvina","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Kyoo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuvayu S","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"ref1","unstructured":"Genetics Home Reference. Neurofibromatosis type 1. Available from: https:\/\/ghr.nlm.nih.gov\/condition\/neurofibromatosis-type-1#statistics.. Accessed May 3, 2020."},{"key":"ref2","first-page":"689","volume":"9","author":"Menon","year":"1990","journal-title":"Cancer Surv"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1750-3639.1990.tb00636.x","volume":"1","author":"Menon","year":"1990","journal-title":"Brain Pathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-pathol-052016-100228","volume":"12","author":"Monroe","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45(5):575\u2013578. doi:10.1001\/archneur.1988.00520290115023","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/glia.20776","volume":"56","author":"Carroll","year":"2008","journal-title":"Glia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"Friedman","year":"1997","journal-title":"Am J Med Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.1200\/JCO.2018.36.15_suppl.10503","volume":"36","author":"Gross","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e3181bd1326","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","volume":"31","author":"Canavese","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"ref16","unstructured":"Food and Drug Administration. FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. 2020. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas. Accessed June 2, 2020."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/jmg.26.11.704","volume":"26","author":"Huson","year":"1989","journal-title":"J Med Genet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"ref23","unstructured":"Lemberg K Lower height percentiles in neurofibromatosis type 1 (NF1) patients on the NCI NF-1 natural history study inversely correlate with plexiform neurofibroma (PN) tumor volume. Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref24","unstructured":"Williams V Plexiform neurofibromas in 150 complex NF1 patients 2017-2018. Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2008.061051","volume":"46","author":"Tucker","year":"2009","journal-title":"J Med Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpeds.2013.10.081","volume":"164","author":"Dagalakis","year":"2014","journal-title":"J Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajmg.a.37987","volume":"173","author":"Lai","year":"2017","journal-title":"Am J Med Genet A"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jpeds.2018.10.019","volume":"206","author":"Lai","year":"2019","journal-title":"J Pediatr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167A","author":"Wolters","year":"2015","journal-title":"Am J Med Genet A"},{"key":"ref32","unstructured":"Rosser T Substantial pain and reduced quality of life (QoL) in adolescents and young adults (AYA) with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) enrolled in NF Consortium PN clinical trials. Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1046\/j.1365-2133.2000.03543.x","volume":"142","author":"Wolkenstein","year":"2000","journal-title":"Br J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"Weiss","year":"2015","journal-title":"Neuro Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nou004","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/now158","volume":"19","author":"Jakacki","year":"2017","journal-title":"Neuro Oncol"},{"key":"ref39","unstructured":"Moertel C Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: a phase I\/IIa study. Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"ref41","unstructured":"Fisher M Neurofibromatosis Clinical Trials Consortium (NFCTC) phase II study of cabozantinib (XL184) for neurofibromatosis type 1 (NF1) associated plexiform neurofibromas. Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref42","unstructured":"Wolters P Prospective patient-reported outcomes (PROs) document clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs) on SPRINT: a phase II trial of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886). Joint Global Neurofibromatosis Conference. Paris, France; 2018."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/gim.2013.30","volume":"15","author":"Nguyen","year":"2013","journal-title":"Genet Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41525-018-0070-7","volume":"3","author":"Chan","year":"2018","journal-title":"NPJ Genom Med"}],"container-title":["Adolescent Health, Medicine and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69581","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T03:06:11Z","timestamp":1621393571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/natural-history-and-disease-burden-of-neurofibromatosis-type-1-with-pl-peer-reviewed-fulltext-article-AHMT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2147\/ahmt.s303456","relation":{},"ISSN":["1179-318X"],"issn-type":[{"value":"1179-318X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}